?

Xenetic Biosciences plc

(the "Company")

Exercise of Options

Xenetic Biosciences plc (AIM: "XEN"), today announces that it has applied for 173,059 new ordinary shares of 0.5 pence each to be admitted to trading on AIM as a result of the exercise of an employee option award. Admission of the new shares is expected to take place on 10 January 2014.

The Company's issued share capital, as stated in the RNS on 6 January 2014, consists of 408,048,487 ordinary shares each with one voting right. The Company does not hold any ordinary shares in treasury.

Enquiries:

Xenetic Biosciences plc

www.xeneticbio.com

M. Scott Maguire, Chief Executive Officer

+44 (0)20 3021 1500

Colin Hill, Chief Financial Officer


London Bridge Capital (Financial Adviser to Xenetic)

+44 (0)7912 201639

Adam Hart




N+1 Singer(Nominated Adviser & Broker)

+44 (0)20 7496 3000

Aubrey Powell




Walbrook PR

+44 (0)20 7933 8780

Mike Wort (Media Enquiries)

mike.wort@walbrookpr.com

Paul Cornelius (Investor Enquiries)

paul.cornelius@walbrookir.com


This information is provided by RNS
The company news service from the London Stock Exchange
ENDMSCUGUBGGUPCURM
distributed by